These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 34411235)

  • 1. Medical therapies for prevention of cardiovascular and renal events in patients with atrial fibrillation and diabetes mellitus.
    Fauchier L; Boriani G; de Groot JR; Kreutz R; Rossing P; Camm AJ
    Europace; 2021 Dec; 23(12):1873-1891. PubMed ID: 34411235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atrial Fibrillation, Type 2 Diabetes, and Non-Vitamin K Antagonist Oral Anticoagulants: A Review.
    Plitt A; McGuire DK; Giugliano RP
    JAMA Cardiol; 2017 Apr; 2(4):442-448. PubMed ID: 28122078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-Glucose Cotransporter-2 Inhibitor Prevents Stroke in Patients With Diabetes and Atrial Fibrillation.
    Chang SN; Chen JJ; Huang PS; Wu CK; Wang YC; Hwang JJ; Tsai CT
    J Am Heart Assoc; 2023 May; 12(10):e027764. PubMed ID: 37183872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between sodium-glucose cotransporter-2 inhibitors and arrhythmic outcomes in patients with diabetes and pre-existing atrial fibrillation.
    Fichadiya A; Quinn A; Au F; Campbell D; Lau D; Ronksley P; Beall R; Campbell DJT; Wilton SB; Chew DS
    Europace; 2024 Mar; 26(3):. PubMed ID: 38484180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists.
    Scheen AJ
    Diabetes Metab; 2022 Nov; 48(6):101390. PubMed ID: 36170946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of sodium-glucose co-transporter-2 inhibitors on dementia and cardiovascular events in diabetic patients with atrial fibrillation.
    Chen YY; Chang HC; Lin YJ; Chien KL; Hsieh YC; Chung FP; Lin CH; Lip GYH; Chen SA
    Diabetes Metab Res Rev; 2024 Feb; 40(2):e3775. PubMed ID: 38340046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated care and outcomes in patients with atrial fibrillation and comorbidities.
    Proietti M; Vitolo M; Lip GYH
    Eur J Clin Invest; 2021 Jun; 51(6):e13498. PubMed ID: 33482011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Sodium-Glucose Cotransporter Inhibitors on Major Adverse Cardiovascular Events and Hospitalization for Heart Failure in Patients With Type 2 Diabetes Mellitus and Atrial Fibrillation.
    Kwon CH; Kim YJ; Kim MJ; Cha MJ; Cho MS; Nam GB; Choi KJ; Kim J
    Am J Cardiol; 2022 Sep; 178():35-42. PubMed ID: 35810007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
    Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
    BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Atrial Fibrillation and Diabetes Mellitus: the Control of Thromboembolic Risk].
    Obrezan AG; Kulikov NV
    Kardiologiia; 2020 Aug; 60(7):108-114. PubMed ID: 33155949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral anticoagulation across diabetic subtypes in patients with newly diagnosed atrial fibrillation: A report from the GARFIELD-AF registry.
    Bassand JP; Virdone S; Camm AJ; Fox KAA; Goldhaber SZ; Goto S; Haas S; Hacke W; Kayani G; Keltai M; Misselwitz F; Pieper KS; Turpie AGG; Verheugt FWA; Kakkar AK;
    Diabetes Obes Metab; 2023 Oct; 25(10):3040-3053. PubMed ID: 37435777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age threshold for the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation: insights into the optimal assessment of age and incident comorbidities.
    Chao TF; Lip GYH; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Liao JN; Chung FP; Chen TJ; Chen SA
    Eur Heart J; 2019 May; 40(19):1504-1514. PubMed ID: 30605505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score = 0 in a community-based cohort study.
    Taillandier S; Olesen JB; Clémenty N; Lagrenade I; Babuty D; Lip GY; Fauchier L
    J Cardiovasc Electrophysiol; 2012 Jul; 23(7):708-13. PubMed ID: 22268375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The connubium among diabetes, chronic kidney disease and atrial fibrillation.
    Magnocavallo M; Vetta G; Trivigno S; Mariani MV; DI Lullo L; Bellasi A; Della Rocca DG; Severino P; Piro A; Giunta G; Quaglione R; Lavalle C
    Minerva Cardiol Angiol; 2022 Jun; 70(3):393-402. PubMed ID: 35212508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-glucose cotransporter-2 inhibitors and the risk of atrial fibrillation in patients with type 2 diabetes: a population-based cohort study.
    Eroglu TE; Coronel R; Souverein PC
    Eur Heart J Cardiovasc Pharmacother; 2024 Jul; 10(4):289-295. PubMed ID: 38520149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk.
    Potpara TS; Lip GY
    Prog Cardiovasc Dis; 2015; 58(2):177-94. PubMed ID: 26162958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).
    Lip GYH; Collet JP; Caterina R; Fauchier L; Lane DA; Larsen TB; Marin F; Morais J; Narasimhan C; Olshansky B; Pierard L; Potpara T; Sarrafzadegan N; Sliwa K; Varela G; Vilahur G; Weiss T; Boriani G; Rocca B;
    Europace; 2017 Nov; 19(11):1757-1758. PubMed ID: 29096024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of atrial fibrillation in patients with chronic kidney disease in Europe Results of the European Heart Rhythm Association Survey.
    Potpara TS; Lenarczyk R; Larsen TB; Deharo JC; Chen J; Dagres N;
    Europace; 2015 Dec; 17(12):1862-7. PubMed ID: 26733617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices.
    Savelieva I; Bajpai A; Camm AJ
    Ann Med; 2007; 39(5):371-91. PubMed ID: 17701479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.